LeukoDX becomes Accellix

Accellix expands leadership team and announces a name change

Register for free to listen to this article
Listen with Speechify
SAN JOSE, Calif. & JERUSALEM—LeukoDX Inc. is pleased to announce their official name change to Accellix, Inc., effective immediately. The newly renamed Accellix is dedicated to developing and commercializing the Accellix platform to enable its growing list of customers in the field of cell and gene therapy to meet their critical quality control (QC) requirements as they advance life changing therapies benefitting patients worldwide.
The company also announced recent major additions to its senior leadership team with the appointment of Nir Nimrodi as executive chairman and Rey Mali as vice president of sales and marketing.
Nimrodi joined Accellix as its executive chairman in June 2019. He brings to Accellix 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical and biotechnology industries. In his most recent role, Nimrodi served as the chief business officer of Intrexon Corporation, the global leader in synthetic biology.
“The change of our name to Accellix completes our re-focusing evolution. We want to make it clear to our customers that we are committed to enabling their critical QC requirements,” Nimrodi said. “Aligned with our customers, we understand that each patient batch they process is precious. Applying our multi-parametric cell analysis system, as part of the process of releasing cells to treat a patient, will be the culmination of everything we aim to achieve and why we exist. We look forward to continued progress in developing our system and to commercializing it with cell and gene therapy companies globally.”
“The cell therapy market needs a new testing paradigm that can deliver rapid results when needed, and one that can scale to meet the expanding adoption of therapy regimens. The Accellix platform is designed for this need and is validated by market leading companies,” noted Mali.
Mali is joining the company as its Vice President Sales and Marketing. She has served as a Product Development and Marketing leader for the past 14 years in both hi-tech and biotech companies. Mali has most recently been working at the Chan Zuckerberg Initiative (CZI) leading the Product Marketing efforts of free technological tools to advance medical research. Before that, she was Sr. Product Marketing Manager at Illumina where she launched and managed products in the sequencing space, and later served as the Product Marketing Director at Twist Bioscience leading the global marketing team towards commercial product launches and a successful IPO.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue